

1 **Guillain-Barré syndrome following Zika virus infection is associated with a diverse**
2 **spectrum of peripheral nerve reactive antibodies**

3 Alexander J Davies^{1*}, Cinta Lleixà^{2*}, Ana M. Siles^{2,3}, Dawn Gourlay⁴, Georgina Berridge⁵,
4 Wanwisa Dejnirattisai⁶, Carolina Ramírez-Santana⁷, Juan-Manuel Anaya⁷, Andrew K.
5 Falconar⁸, Claudia M. Romero-Vivas⁸, Lyda Osorio⁹, Beatriz Parra⁹, Gavin R. Screaton⁶,
6 Juthathip Mongkolsapaya^{6,10}, Roman Fischer⁵, Carlos A. Pardo¹⁰, Susan K. Halstead⁴, Hugh
7 J. Willison⁴, Luis Querol^{2,3†}, Simon Rinaldi^{1†}

- 8 1) Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe
9 Hospital, Oxford, UK
10 2) Neuromuscular Diseases Unit, Neurology Department, Hospital de la Santa Creu i Sant
11 Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
12 3) Centro para la Investigación Biomédica en red en Enfermedades Raras – (CIBERER)
13 Madrid, Spain
14 4) Institute of Infection, Immunity & Inflammation, University of Glasgow, University Place,
15 Glasgow, UK
16 5) Target Discovery Institute, NDM Research Building, University of Oxford, Old Road
17 Campus, Oxford, UK
18 6) Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of
19 Oxford, Oxford, UK
20 7) Center for Autoimmune Diseases Research (CREA), Universidad del Rosario, Bogotá,
21 Colombia
22 8) Departamento de Medicina, Universidad del Norte, Barranquilla, Colombia
23 9) Grupo de Epidemiología y Salud Poblacional (GESP), School of Public Health,
24 Universidad del Valle, Cali, Colombia
25 10) Dengue Hemorrhagic Fever Research Unit, Office for Research and Development,
26 Siriraj Hospital, Faculty of Medicine, Mahidol University, Bangkok, Thailand
27 11) Department of Neurology, Johns Hopkins University School of Medicine, Baltimore,
28 United States

29 */† these authors contributed equally to this work.

30 Word count: 4253

31

32 **Corresponding authors:**

33 Dr Simon Rinaldi, Nuffield Department of Clinical Neurosciences, University of Oxford, Level
34 6, West Wing, John Radcliffe Hospital, Oxford, UK. OX3 9DU.

35 Email: simon.rinaldi@ndcn.ox.ac.uk

36

37 Dr Luis Querol, Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona,

38 Mas Casanovas 90, 08041, Barcelona, Spain.

39 Email: lquerol@santpau.cat

40 **ABSTRACT**

41

42 **Introduction**

43 Recent outbreaks of Zika virus (ZIKV) in South and Central America have highlighted
44 significant neurological side effects. Concurrence with the inflammatory neuropathy Guillain-
45 Barré syndrome (GBS) is observed in 1:4000 ZIKV cases. Whether the neurological
46 symptoms of ZIKV infection are a consequence of autoimmunity or direct neurotoxicity is
47 unclear.

48

49 **Methods**

50 We employed rat dorsal root ganglion (DRG) neurons, Schwann cells (SCs), and human
51 stem cell-derived sensory neurons myelinated with rat SCs as cellular models to screen for
52 IgG and IgM autoantibodies reactive to peripheral nerve in sera of ZIKV patients with and
53 without GBS. In this study, 52 ZIKV-GBS patients were compared with 134 ZIKV-infected
54 patients, and 91 non-ZIKV controls. Positive sera were taken forward for target identification
55 by immunoprecipitation and mass spectrometry, and candidate antigens validated by ELISA
56 and cell-based assays. Autoantibody reactions against glycolipid antigens were also
57 screened on an array.

58

59 **Results**

60 Overall, IgG antibody reactivity to rat SCs (6.5%) and myelinated co-cultures (9.6%) were
61 significantly higher, albeit infrequently, in the ZIKV-GBS group compared to all controls. IgM
62 antibody immunoreactivity to DRGs (32.3%) and SCs (19.4%) was more frequently
63 observed in the ZIKV-GBS group compared to other controls, while IgM reactivity to co-
64 cultures was as common in ZIKV and non-ZIKV sera. Strong axonal-binding ZIKV-GBS
65 serum IgG antibodies from one patient were confirmed to react with neurofascin-155 and
66 186. Serum from a ZIKV non-GBS patient displayed strong myelin-binding and anti-lipid
67 antigen reaction characteristics. There was no significant association of ZIKV-GBS with any
68 anti-glycolipid antibodies.

69

70 **Conclusion**

71 Autoantibodies in ZIKV associated GBS patients' sera target heterogeneous peripheral
72 nerve antigens suggesting heterogeneity of the humoral immune response despite a
73 common prodromal infection.

74

75

76 INTRODUCTION

77 Zika virus (ZIKV) is a member of the Flavivirus family that is transmitted by *Aedes* spp.
78 mosquito vector species and in humans typically results in asymptomatic or mildly
79 symptomatic infections. An outbreak of ZIKV infections in French Polynesia in 2013 was
80 followed by a spike in the diagnoses of the disabling, acute inflammatory neuropathy
81 Guillain-Barré syndrome (GBS). Early case control studies established one excess GBS
82 case for every 4000 people infected with ZIKV.[1] By 2015, the ZIKV pandemic reached
83 South America, where in Colombia the GBS incidence rates were increased by 210-350%
84 compared to the pre-ZIKV period.[2, 3] The overall risk estimates range from 1 to 8 GBS
85 cases per 10,000 ZIKV infections.[4] Recent studies estimate that the total number of ZIKV
86 infections during the 2015-16 outbreak was much higher than originally reported, suggesting
87 previous incidence rates of GBS per infection may have been substantially
88 underestimated.[5]

89 The onset of GBS post-ZIKV infection (ZIKV-GBS) occurred within a median of 6 days after
90 a transient febrile illness, though the peak incidence of GBS cases was observed 3 weeks
91 after the peak of ZIKV diagnoses.[1, 2] Whether this represents an infectious, para-infectious
92 or post-infectious aetiology has been debated. Electrophysiological studies performed on 37
93 ZIKV-GBS patients identified in French Polynesia showed characteristics consistent with the
94 acute motor axonal form of GBS (AMAN).[1] However, follow-up studies at 4 months were
95 more suggestive of distal demyelination.[6] In a Colombian series, 70% of ZIKV-GBS cases
96 were classified as acute inflammatory demyelinating polyradiculoneuropathy (AIDP),
97 suggestive of immune-mediated injury.[7] ZIKV has also been linked to a number of central
98 and peripheral neurological complications, all of which may have an autoimmune
99 mechanism [8].

100 A potential role for ZIKV-induced autoimmunity is supported by similarities between the ZIKV
101 E protein and human complement component C1q *in silico*, and the presence of C1q
102 antibodies in the sera of animals infected with the virus.[9] Lynch and colleagues observed
103 higher-titre antibody responses to ZIKV in patients who developed GBS, compared to those
104 with uncomplicated infections.[10] More recently, a higher incidence of anti-ganglioside
105 antibodies was identified in a Brazilian cohort of ZIKV-GBS patients compared to
106 uncomplicated ZIKV controls [11] suggesting an association between nerve reactive
107 autoantibodies and the peripheral neurological complications of ZIKV.

108 The peripheral neurology associated with ZIKV infection may also occur via direct viral
109 toxicity.[12] ZIKV directly infected peripheral neurons and induced cell death in both mouse

110 and cell culture models.[13], as well as infecting sensory neurons and Schwann cells (SCs)
111 in dorsal root ganglia (DRG) explants from interferon receptor-1 knockout mice leading to
112 myelin fragmentation and later axonal degeneration.[14]

113 In this study, we sought to address the potential for humoral autoimmunity in ZIKV-GBS by
114 screening sera from a large cohort of ZIKV-GBS patients and controls for nerve reactive
115 immunoglobulins using a range of animal and humanised nerve cell cultures and antigen
116 detection methods.

117 **MATERIALS & METHODS**

118 Full details of this section are available in Supplementary Material and Data files.
119

120 **Patient cohorts and sample acquisition**

121 Serum samples were collected from patients with ZIKV infection both with and without
122 neurological complications, as well as from other infectious, healthy and convalescent
123 controls from the Cucuta, Cali and Barranquilla regions of Colombia, the UK (South Central -
124 Oxford A approval number 14/SC/0280) and Spain (The Sant Pau Biomedical Research
125 Institute approval number IIBSP-AUT-2016-69) (**Supplementary Figure 1** and
126 **Supplementary Table 1**). ZIKV-GBS patients were classified according to previously
127 published electrodiagnostic criteria, [7] with full characterisations previously reported for
128 Cucuta [15] and Cali cohorts. [3] Serum samples were aliquoted and stored at -80°C. This
129 study was carried out and reported in accordance with the STROBE guidelines.[16]

130 **Rat DRG neuron and SC culture and immunocytochemistry**

131 Rat DRG neurons and SCs were extracted in accordance with Schedule 1 of the UK Home
132 Office Animals (Scientific Procedures) Act 1986, and Animal Ethics' Committee of Hospital
133 de la Santa Creu i Sant Pau. Cells were cultured, and immunocytochemistry was performed
134 as previously described.[17] Fluorescence signal intensities were scored on a 0–3 scale by
135 two independent researchers.

136 **Myelinating co-cultures and immunofluorescence labelling**

137 Myelinating co-cultures were prepared using human induced pluripotent stem cell (hiPSC)-
138 derived sensory neurons and neonatal rat SCs as previously described.[18, 19] Sera from
139 ZIKV-exposed subjects was diluted to 1:100 and added to live co-cultures for 1h at 37°C.
140 Fixed cultures were probed with either anti-human IgG, anti-human IgM or anti-human

141 complement C3c antibodies. Confocal images were assessed for IgG or IgM reactivity by a
142 blinded observer.

143 **Assessment of serum-induced demyelination**

144 Myelinating co-cultures were incubated for 1h in 'complete' neurobasal media supplemented
145 with fluoromyelin red. Serum-free myelination medium was then supplemented with or
146 without human anti-ZIKV patients' sera at a 1:100 dilution together with 20% normal human
147 serum (NHS) as a source of complement and added to the co-cultures.

148 **Glycoarray**

149 Serum samples were also screened on a glycolipid microarray as previously described.[20]
150 For this study, sera were screened against a panel of 16 single glycolipids (GM1, GM2,
151 phosphatidylserine, GM4, GA1, GD1a, GD1b, GT1a, GT1b, GQ1b, GD3, SGPG, LM1,
152 cholesterol, GalC and sulphatide) and 120 heteromeric 1:1 (v:v) complexes, printed in
153 duplicate.

154 **Immunoprecipitation and mass spectrometry**

155 Human sera showing moderate or strong reactivity against rat DRG neurons or myelinating
156 co-cultures were used for immunoprecipitation (IP) experiments using the same target cell
157 type, as previously reported.[17] For the mass spectrometry analyses, the IP eluates from
158 myelinating co-cultures were prepared by chloroform:methanol precipitation and in-solution
159 trypsin digestion. The resultant peptides were then subjected to high resolution C18 reverse-
160 phase column chromatography and analysed by data-dependant MS/MS on a ThermoFisher
161 Fusion Lumos mass spectrometer. Raw data are available via ProteomeXchange with
162 identifier PXD028476.

163 **Protein electrophoresis and Western blot**

164 The lysates from myelinating co-cultures, hiPSC-derived sensory neurons monocultures,
165 and primary rat SCs were subjected to electrophoresis in acrylamide gels using MOPS
166 running buffer under denaturing, non-reducing conditions and then transferred to a
167 nitrocellulose membrane. These blots were probed with using patients' sera at a 1:2500
168 dilution followed by HRP-conjugated Fc-specific anti-human-IgG secondary antibody. The
169 bands detected by western blotting were aligned in a parallel gel stained with Pierce Imperial
170 Protein Stain and excised for mass spectrometry.

171 **ELISA**

172 Recombinant human nidogen-1, laminins 111, 121, 211, 221, 411, 421, 511 and 521,
173 prosaposin and vinculin were coated at 1 µg/ml (100 µl per well) in Maxisorp ELISA plates
174 overnight at 4°C (See **Supplementary Table 2** for details). The ganglioside GM3 ELISA was
175 performed as previously described [21]. For the detection of anti-ZIKV antibodies, Maxisorp
176 plates were coated with the anti-flavivirus mouse monoclonal antibody 4G2 and performed
177 as previously described.[22] Bound human IgG antibodies were detected through sequential
178 steps using Fc-specific HRP-conjugated secondary antibodies and substrate.

179 **Transfected-cell based assays**

180 HEK293 cells were transfected overnight using JetPEI with mammalian expression vectors
181 encoding human AHNAK2, ANXA2, CD44S, CNTN1, CASPR1, GFRA1, ITGA6, ITGA7,
182 MAG, NEP, NFASC, NKCC1, PRX, TGBR3 (**Supplementary Table 3**), or using
183 Lipofectamine 2000 for human ALCAM, AXL, DPYSL2, GAS6, L1CAM, NCAM1 and NrCAM
184 (**Supplementary Table 4**). Sera were diluted 1:100 and IgG binding was assessed using
185 fluorescent-conjugated anti-human IgG secondary antibodies.

186 **Statistical analysis**

187 The results were analysed in Prism v9.1.0 (GraphPad). Statistical comparisons of the
188 proportions of seropositive patients among ZIKV groups were performed using contingency
189 analyses with the application of a two-tailed Fisher's exact test for individual group-group
190 comparisons, and Chi square testing for comparisons between all groups.

191

192

193

194 **RESULTS**

195 **Patient cohorts**

196 Serum samples were obtained from a total of 218 Colombian subjects: 52 patients with GBS
197 and confirmed ZIKV infection (ZIKV-GBS), 17 patients with ZIKV infection and other
198 inflammatory neurological diseases (ZIKV-OND), 117 ZIKV-infected patients without
199 neurological complications (ZIKV-CON), and a control group (CON) formed by 23 patients
200 with Dengue virus (DENV) infections (DENV-CON) from Cali and 9 healthy controls from
201 Cucuta. An additional 38 serum samples (5 ALS and 5 Dysferlin patients, and 28 healthy
202 controls) from Spanish subjects and 21 healthy controls from the UK were also used
203 **(Supplementary Figure 1).**

204 Overall, the patients with ZIKV-GBS were slightly older and less often female
205 **(Supplementary Table 1)**. ZIKV capture ELISA showed the presence of anti-ZIKV IgG in all
206 ZIKV-GBS, ZIKV-OND and ZIKV-CON patients' sera tested, as well as the DENV patients'
207 sera, probably due to the likely cross-reactivity of DENV and ZIKV patients' antibodies [22]
208 **(Supplementary Figure 2)**.

209 **Microarray screening for glycolipid complex antibodies**

210 ZIKV-associated patients' sera were screened against a panel of glycolipids using a
211 combinatorial glycoarray for the presence of IgG **(Supplementary Figure 3A)** and IgM
212 **(Supplementary Figure 3B)** anti-glycolipid antibodies.

213 Overall, the glycolipid array revealed only weak binding intensities against the panel of 136
214 unique glycolipid targets, including known gangliosides implicated in GBS, none of which
215 were found to be statistically associated with post-ZIKV GBS. Two ZIKV-GBS samples were
216 found to contain IgG antibodies against various gangliosides at elevated levels, as typically
217 seen in GBS and its clinical variants. This included a single ZIKV-GBS sample with anti-
218 disialosyl IgG (GQ1b, GT1a and GD3) normally associated with the GBS subtype Miller-
219 Fisher syndrome; another with anti-GM1 IgG, typically present in the clinical subtype AMAN.
220 It is possible that these cases may represent a temporal co-infection of *Campylobacter* and
221 *Flavivirus*, resulting in a classic IgG antibody signature for these patients.

222 **Screening against rat DRG neurons and Schwann cells**

223 Moderate or strongly rat DRG reactive IgM autoantibodies were observed in proportionally
224 more sera of ZIKV-GBS patients compared to the ZIKV-OND, ZIKV-CON patients and other

225 controls (CON) groups (**Table 1**). On the other hand, moderate or strong IgG autoantibody
 226 reactivity against DRG neurons were not statistically different between these groups. With
 227 the SCs, a greater proportion of moderate or strong IgG and IgM reactivity was observed in
 228 ZIKV-GBS patients' sera compared to other uncomplicated ZIKV patients and control groups
 229 (**Table 1**).

230 Overall, there was a greater chance of observing any anti-peripheral nerve cell IgG or IgM
 231 antibody reactivity in the ZIKV-GBS and ZIKV-OND patients' sera, compared to non-
 232 complicated ZIKV (ZIKV-CON) and non-ZIKV control (CON) groups. These differences
 233 between groups were statistically significant ($p=0.0009$, Chi square test).

234 Additionally, we observed that IgG and IgM binding to DRG neurons or SCs were
 235 significantly more common in the ZIKV-GBS patients' sera than in the ZIKV-CON group's
 236 sera ($p=0.0042$, Fisher's exact test); whereas there was no significant difference in the
 237 proportions of grouped anti-ZIKV sera and non-ZIKV sera ($p>0.05$, Fisher's exact test) (see
 238 **Figure 1** for multiple comparisons).

239 **Table 1. Statistical analysis of serum immunoreactivity to DRG neurons and SC**
 240 **cultures.**

		ZIKV - GBS (n = 31)		ZIKV-OND (n = 12)		ZIKV-CON (n = 77)		CON (n = 43)		Chi-square p value	
		All positives	Moderate to strong positives	All positives	Moderate to strong positives	All positives	Moderate to strong positives	All positives	Moderate to strong positives	All positives	Moderate to strong positives
DRG neurons	IgG	22 (71%)	5 (16.1%)	7 (58.3%)	2 (16.7%)	28 (36.4%)	3 (3.9%)	16 (37.2%)	3 (7%)	0.0054 (**)	0.1193
DRG neurons	IgM	28 (90.3%)	10 (32.3%)	12 (100%)	2 (16.7%)	21 (27.3%)	3 (3.9%)	14 (32.6%)	0	<0.0001 (***)	<0.0001 (***)
Schwann cells	IgG	3 (9.7%)	2 (6.5%)	0	0	6 (7.8%)	0	3 (7%)	0	0.7464	0.0348 (*)
Schwann cells	IgM	19 (61.3%)	6 (19.4%)	5 (41.7%)	0	35 (45.5%)	6 (7.8%)	16 (37.2%)	0	0.2256	0.0121 (*)
Any reactivity	IgG/ IgM	31 (100%)	12 (38.7%)	12 (100%)	4 (33.3%)	54 (70.1%)	8 (10.4%)	30 (69.8%)	3 (7%)	0.0009 (***)	0.0004 (***)

241

242 Screening against myelinating co-cultures

243 IgM binding to myelinating co-cultures was frequently detected with both the ZIKV-GBS
 244 patients' and control group's sera (**Table 2 and Supplementary Figure 2**). IgM reactivity
 245 was observed against the abaxonal membranes of myelinating SCs, axons, the processes of
 246 the non-myelinating SCs, as well as outpouchings of myelin (**Supplementary Figures 4A**
 247 **and B**). Overall, there was no significant difference in the proportions of ZIKV-GBS patients'
 248 and control sera in terms of the frequency or pattern of positive IgM reactivity ($p=0.3374$,
 249 Fisher' exact test) (see **Table 2** for multiple comparisons). IgM labelling of myelin
 250 outpouchings varied in intensity between the samples (**Supplementary Figures 4C and D**),
 251 however, immunofluorescence intensity at the myelin outpouchings normalised to the
 252 internode (**Supplementary Figures 4E and F**) was not significantly different between the
 253 ZIKV-GBS patients', the ZIKV-CON patients' or the healthy control group's serum sample
 254 (One way ANOVA, $F(2,106)=0.7417$, $p=0.4788$) (**Supplementary Figure 4G**).

255 **Table 2. Frequency and statistical analysis of myelinating co-culture**
 256 **immunoreactivity.**
 257

Myelinating co-culture reactivity		Samples with positive immunoreactivity by pattern					
		Myelin / abaxonal	Myelin outpouchings	Schwann cell	Nodal / Axonal	Any	
Antibody class	IgG	ZIKV-GBS (n=52)	4 (7.7%)	1 (1.9%)	0	1 (1.9%)	5 (9.6%)
		ZIKV-CON (n=117)	1 (0.9%)	0	0	0	1 (0.9%)
		ZIKV-OND (n=17)	0	0	0	0	0
		CON (n=53)	0	0	0	0	0
		Chi-square P value	0.0213(*)	0.3066	-	0.3066	0.0027(**)
	IgM	ZIKV-GBS (n=52)	2 (3.8%)	7 (13.5%)	4 (7.7%)	1 (1.9%)	12 (23.1%)
		ZIKV-CON (n=117)	1 (0.9%)	25 (21.4%)	6 (5.1%)	0	32 (27.1%)
		ZIKV-OND (n=17)	0	1 (5.9%)	2 (11.8%)	0	3 (17.6%)
		CON (n=53)	0	7 (13.2%)	2 (3.8%)	0	8 (15.1%)
		Chi-square P value	0.2773	0.2497	0.5885	0.3066	0.3347

258

259

260 IgG antibody reactivity was observed against different topographical domains within the co-
261 cultures. Four out of 52 (7.7%) ZIKV-GBS patients' sera contained IgG which bound the
262 abaxonal membrane of a subset of myelinating SCs (**Table 2**), whilst showing no reactivity
263 against non-myelinating SCs or axons (**Figures 2A and B**).

264 IgG from one ZIKV-GBS patient serum (male, 16-20 years old) was deposited on non-
265 compact myelin at the paranodes and Schmidt-Lanterman incisures (**Figure 2C**). One ZIKV-
266 GBS patient's sera (patient A, male, 41-45 years old) labelled the axons of cultured neurons
267 and their IgG antibody deposition was particularly concentrated at the nodal axolemma
268 (**Figure 2D**). These patterns of IgG autoantibody reactivity were never seen with the control
269 sera. The serum of one ZIKV-CON patient (patient B, female, 41-45 years old) also
270 contained IgG antibodies, which gave an intense pattern of immunofluorescence over the
271 abaxonal membranes of all myelinating SCs, and at the nodal microvilli (**Figure 2E**); no IgG
272 labelling from patient B was present sensory neuron or SC monocultures (data not shown).
273 Overall, IgG antibody reactivity against myelinating co-cultures was significantly more
274 common in ZIKV-GBS patients' sera (5/52; 9.6%) compared to all controls (1/187; 0.5%)
275 ($p=0.0021$, Fisher's exact test) (see **Table 2** for multiple comparisons).

276 **Assessment of ZIKV antibody-mediated axonopathy and demyelination**

277 We next investigated the pathological potential of IgG autoantibodies in the two serum
278 samples which reacted strongly against the cell co-cultures: patient A (**Figure 2D**) and
279 patient B (**Figure 2E**). The axon and nodal binding of IgG antibodies present in the patient
280 A's serum was exclusively of the IgG1 subclass (**Supplementary Figure 5A**). The addition
281 of patient A's serum at a 1:100 dilution did not result in any axonal degeneration or other
282 visible morphological nerve injury in the presence of complement in 20% NHS compared to
283 that caused by a known complement-fixing anti-ganglioside IgM positive control antibody
284 (**Supplementary Figure 5B**).

285 Antibodies reactive to myelinating SCs in patient B's serum were also predominantly of the
286 IgG1 subclass, with some IgG4 autoantibody subclass reaction against either SC processes
287 or axons (**Supplementary Figure 6**).

288 The addition of patient B's sera at a 1:100 dilution to co-cultures in the presence of 20%
289 NHS resulted in complement deposition (C3c) around myelin internodes, and myelin
290 fragmentation without apparent axonal degeneration (**Figures 3A, B**). Time-lapse imaging of

291 fluoromyelin-stained internodes revealed retraction of the myelin from the node within hours
292 of exposure to the anti-ZIKV serum in the presence of complement (**Figures 3C, D**). After
293 24h, multiple myelin internodes were either lost completely or significantly fragmented
294 compared to baseline (0h) (**Figure 3E**). Anti-ZIKV serum treatment of the myelinating co-
295 cultures in the presence of complement in the 20% NHS, but not anti-ZIKV serum or NHS
296 alone, led to a significant loss of myelin coverage (**Figure 3F**), increased myelin
297 fragmentation (**Figure 3G**) and shortening of internode length (**Figure 3H**), thereby
298 confirming the effect seen using the time-lapse imaging (**Figure 3D**).

299 **Antigen identification in myelinating co-cultures**

300 The nodal/axonal binding ZIKV-GBS sera of patient A (**Figure 4A**) showed a similar binding
301 pattern to sera from a separate study containing anti-CNTN1 antibodies (**Figure 4B**) [23].
302 Both sera maintained a similar IgG binding pattern when reacted with neuronal
303 monocultures, thereby confirming the neuronal origin of both the unknown ZIKV-GBS auto-
304 antigen (**Figure 4C**) and CNTN1 (**Figure 4D**). No immunolabelling was observed with
305 healthy control serum (**Figure 4E**). In accordance with the nodal IgG labelling observed in
306 the myelinating cell co-cultures, we tested for the nodal/paranodal candidate neurofascin
307 (NF) in cell-based assays. Heterologous expression of NF155 and NF186 isoforms in a HEK
308 cell-based assay confirmed their antigen-specific targeting by IgG1 antibodies in this ZIKV-
309 GBS patient's sera (**Figures 4F, G**) who had succumbed to lethal ZIKV-induced GBS. This
310 'anti-pan-NF protein isoform' IgG autoreactivity pattern was not detected in any of the other
311 ZIKV-GBS patients' or control sera.

312 **Immunoprecipitation**

313 We employed a proteomic approach to identify candidate antigens from our live cell culture
314 screening by isolating antigen-bound IgG antibodies from serum-treated cultures using
315 protein G bead immunoprecipitation (IP) followed by high resolution C18 reversed-phase
316 chromatography mass spectrometry (MS) analyses. We first validated this approach using
317 patient A's serum in neuronal cell monocultures. Three potential antigens were identified as
318 enriched in the IP: NF, NCAM1, and NCAM2 (**Supplementary Data - Tab 1**), confirming that
319 NF was a target antigen of patient A's serum.

320 The abaxonal SCs binding ZIKV-CON patient B's serum was compared with a patient with
321 anti-NF155 antibodies by IP-MS, which showed a similar pattern of IgG binding (**Figures 5A,**
322 **B, C and Supplementary Data – Tab 2**). A total of 28 proteins were significantly enriched

323 by patient B's sera including some complement components and seven membrane-related
324 proteins: ANXA2, TGFBR3, NKCC1, NEP, CD44, ITGA6 and AHNAK2 (**Figure 5C**).

325 Sera from two of the ZIKV-GBS patients (patient C and patient D) which showed moderate
326 or strong reactivity against primary DRG neurons, and one from a healthy control, were also
327 taken forward for IP-MS analysis. Antigen-bound IgG antibodies from patient C's sera (
328 **Supplementary Data - Tab 3**) and patient D's sera (**Supplementary Data – Tab 4**), or
329 secondary IgG anti-IgM bound to patient D's IgM neurone autoreactive antibodies (
330 **Supplementary Data – Tab 5**) were isolated from DRG neurons lysates by IP and
331 processed for MS. In this study, six potential autoantigens (ALCAM, DPYSL2, NCAM1,
332 CNTN1, L1CAM, VINC) were identified as enriched by these anti-ZIKV sera compared to the
333 control sera.

334 **Evaluation of candidate antigens**

335 Candidate antigens identified by IP-MS were evaluated by either ELISA or by heterologous
336 expression in live cell-based assays. ELISA using human recombinant prosaposin and GM3
337 (alone or in combination), multiple human laminin isoforms and nidogen-1 failed to confirm
338 these as targets of patient B's serum IgG autoantibodies (**Supplementary Table 2**).

339 Heterologous expression in HEK cells failed to reveal binding of ZIKV-CON patient B's
340 serum IgG antibodies to ANXA2 (**Figure 5D**) or any of the large number of other candidate
341 proteins in ELISA (**Supplementary Table 2**). Furthermore, neither ZIKV-GBS patient C's or
342 D's serum IgG or IgM antibodies reacted against any of the candidate antigens by
343 heterologous expression in these cell-based assays (**Supplementary Table 3**). We
344 additionally analyzed IgG and IgM reactivity of anti-ZIKV sera against GAS6 and AXL
345 proteins, which have been described as the receptors ZIKV virus entry to human neural cells
346 as well as NrCAM, which shares 6 common peptide sequences with the ZIKV polyprotein.
347 However, none of these sera reacted against these three candidate antigens or members of
348 the AXL-GAS6 complex (**Supplementary Table 3**).

349 To account for the potential loss of antigen during the IP process, we subjected the lysates
350 of myelinating cell co-cultures to electrophoresis on an acrylamide gel and after electro-
351 blotting on nitrocellulose membranes the reactions of patient B's sera autoantibodies were
352 tested against these nerve cell antigens. Through this western blotting analysis, the
353 patients' IgG antibodies reacted strongly with two bands (**Supplementary Figure 7**). Manual
354 filtering for membrane proteins associated with SCs or myelination identified three potential
355 target antigens: PRX, ITGA7 and GFRA1 (**Supplementary Data – Tab 6**). However, no IgG

356 reactivity to these particular antigens was observed using patient B's serum on transiently-
357 transfected cell-based assays (**Supplementary Table 2**).

358 **Chemical and enzymatic characterisation of target antigens**

359 The intense labelling of the patient B's serum in the lipid rich membrane and nodal microvilli
360 of myelinating SCs (**Figure 6A**) led us to further investigate the target antigen characteristics
361 using a biochemical approach. Solvent extraction of lipids from serum-treated and fixed
362 myelinated co-cultures with mixture of chloroform, methanol and water as described
363 previously [24] significantly reduced the amount of patient B's serum IgG antibodies which
364 bound to the abaxonal SCs membranes (**Figure 6B, C and D**), while the reactivity of
365 commercial antibodies directed against NF2000 and MBP antigens were retained (**Figure**
366 **6B and C**). Solvent extraction did not affect labelling of human IgG to the GPI-linked protein
367 CNTN1 (**Supplementary Figure 8**). Limited IgG antibody labeling remained at the
368 paranodes (**Figure 6B**). Binding of patient B's IgG antibodies was not however affected by
369 prior neuraminidase treatment of the cell co-cultures (**Supplementary Figure 9**) compared
370 with positive controls (**Supplementary Figure 10**) suggesting that the target antigen was not
371 a sialylated glycolipid.

372

373 **DISCUSSION**

374 Our study found that the humoral immune response in ZIKV-GBS cases was diverse and
375 heterogeneous. We found neither a common antigen nor a common pattern of serum
376 immunoreactivity against peripheral nerve structures despite all of these ZIKV-GBS patients
377 sharing a common prodromal infection.

378 Consistent with a recent study of a modest cohort of ZIKV-associated GBS patients from
379 Brazil,[11] we observed a small number of GBS patients with elevated anti-glycolipid IgG
380 antibodies. However, we did not find a significant statistical association of ZIKV-GBS patient
381 cases with any anti-glycolipid antibody signature, thereby supporting the results from a
382 recent cohort study from Northeast Brazil. [25] The cases we did find may represent a
383 subset of ZIKV induced GBS, or merely have been cases of classical onset GBS patients
384 whose clinical course coincided with recent ZIKV infections.

385 Analysis of the ZIKV polyprotein showed that it contained peptide sequences which were
386 also found in human proteins and that are known to be targets of inflammatory neuropathy

387 autoantibodies.[26] However, while all ZIKV patient samples tested contained anti-ZIKV IgG
388 antibodies, anti-nerve reactive autoantibodies showed a more discrete distribution,
389 suggesting that any nerve-related antigenicity was not a consequence of humoral immunity
390 to ZIKV antigens *per se*. Despite the high level of antigenic similarity between flaviviruses,
391 we did not observe any specific nerve cell reactive autoantibodies in the DENV-infected
392 control (DENV-CON) sera, in keeping with the rarity of GBS associated with recent DENV
393 infections.[27] Although we observed one case of anti-pan-NF protein isotype IgG1
394 autoantibodies in our Colombian cohort (ZIKV-GBS patient A), prodromal infection is not a
395 consistent feature of this rare and potentially fatal peripheral neuropathy subtype.[28]

396 By employing a comprehensive series of peripheral nerve cell culture models and antigen
397 expression systems, we reveal a surprisingly heterogeneous autoantibody response in
398 patients' sera. Overall, IgG reactivity to rat SCs and the cell co-cultures was significantly
399 higher, albeit infrequently, in the ZIKV-GBS patient group compared to all controls. IgM
400 reactivity against rat DRG neurons and rat SCs was also significantly higher in ZIKV-GBS
401 patient than in the control group. On the other hand, IgM immunoreactivity to myelin
402 outpouchings, a feature reminiscent of the myelin foldings, swellings or tomaculae
403 sometimes seen in certain hereditary neuropathies,[29] was remarkably common in both the
404 ZIKV-GBS patient and control groups. The significance of these structures in the co-culture
405 system is however unclear.

406 One patient (ZIKV-CON patient B), with an uncomplicated ZIKV infection, displayed striking
407 IgG reactivity against abaxonal membrane of myelinating SCs that was particularly enriched
408 at the nodal villi. These IgG1 subclass antibodies induced profound demyelination in our *in*
409 *vitro* model system via a complement-dependent pathway, despite the patient lacking
410 neurological symptoms. This apparent functional discrepancy might be accounted for by the
411 use of rodent SCs in the co-culture system and a potential lack of cross-reactivity to human
412 SCs, or by the target antigen(s) remaining hidden from circulating antibodies *in situ*.

413 By employing IP-MS in sera-treated myelinating co-cultures and DRG neurons, we revealed
414 a number of candidate antigens related to either SC membranes, myelin formation, or neural
415 cell adhesion. However, we could not confirm any candidate antigen reactivity by these
416 patients IgG or IgM antibodies by either the ELISA or cell-based assays, reinforcing the
417 challenges of antigen identification in the inflammatory neuropathies.[30] Nevertheless, the
418 patterns of immunoreactivity specific to the patient groups, such as nodal, axonal and myelin
419 internodes in the myelinating co-cultures, which were not observed in any control samples,

420 suggest that the near-native antigen conformation in the cell co-culture system is a high-
421 fidelity substrate for screening potentially pathogenic patients' serum IgG antibodies.[19]

422

423 One of the limitations of our study is that our protocols are optimized for proteins and not for
424 lipids. In fact, solvent-based lipid extraction significantly reduced reactivity of patient B's IgG
425 autoantibody reactions against myelinating SCs in the co-culture system, suggesting a
426 lipidomic approach may be required. It is also possible that certain protein antigens were not
427 detectable, either due to poor immunoprecipitation, or lack of representation in the peptide
428 database used to compile our list of candidate antigens. An alternative approach is offered
429 by high throughput antibody screening techniques such as the newly described Rapid
430 Extracellular Antigen Profiling (REAP) technique,[31, 32] or chip-based proteome profiling
431 [33], which has recently offered insights into the autoantibody repertoire of patients with
432 chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).[34]

433

434 Our findings mirror our recent screening of a separate cohort of 100 GBS patients, where we
435 report a similarly heterogeneous reactivity of IgG and IgM to nerve-related antigens.[35] The
436 narrow definition of the present GBS cohort, in which all patients associated with the same
437 infectious insult, suggest that heterogeneity of the humoral immune responses in GBS may
438 be a core feature of the disease and not necessarily due to heterogeneity of the patient
439 cohorts.

440 **Acknowledgements**

441 We thank Professors Peter Brophy and Sarosh Irani for kindly providing the periaxin
442 antibody and healthy human control sera, respectively. We also thank Professor Robert
443 MacLaren, Dr Tina Storm and Dr Ahmed Salman for their generous assistance with the
444 IncuCyte time-lapse imaging. The authors would like to acknowledge the Department of
445 Medicine at the Universitat Autònoma de Barcelona. CLI and LQ are members of the
446 European Reference Network for Neuromuscular Diseases - Project ID No. 870177. pCSC-
447 SP-PW-Nep (aka: pBOB-NEP) was a gift from Inder Verma. CD44S pBabe-puro was a gift
448 from Bob Weinberg. anxA2-GFP was a gift from Volker Gerke & Ursula Rescher. ITGA6-bio-
449 His was a gift from Gavin Wright. pcDNA3.1 Flag YFP hNKCC1 (NT17) was a gift from Biff
450 Forbush. pBabe neo TGFBR3-HA was a gift from Kevin Janes.

451 **Competing interests**

452 SR has received a) a speaker's honoraria from Fresenius, Alnylam and Excemed, and
453 payments to provide expert medicolegal advice on inflammatory neuropathies and their

454 treatment, b) a complimentary registration and prize money from the Peripheral Nerve
455 Society and c) a travel bursary from the European School of Neuroimmunology and is a
456 member of the GBS and Associated Inflammatory Neuropathies (GAIN) patient charity
457 medical advisory board. He also runs a not-for-profit nodal/paranodal antibody testing
458 service at the Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital,
459 Oxford, UK, in partnership with Clinical Laboratory Immunology of Oxford University
460 Hospitals.

461

462

463 **Funding**

464 This work is supported by the Medical Research Council UK (MR/P008399/1) (S.R.); *Fondo*
465 *de Investigaciones Sanitarias (FIS)*, *Instituto de Salud Carlos III*, Spain and FEDER under
466 grant FIS19/01407 and INT20/00080; Wellcome Grant 092805 (S.K.H. and H.J.W.) and by
467 the GBS-CIDP Foundation International. AKF, CMR, LO, BP, CAP, DG, SKH and HJW were
468 also members of a European Union's Horizon 2020 Research and Innovation Program
469 ZikaPLAN grant agreement 734584 and 202789 under which many of the ZIKV-GBS, ZIKV-
470 OND, ZIKV-CON and DENV-CON patients were clinically diagnosed and their serum
471 samples were collected and initially assessed before being transferred to the UK for
472 inclusion in this study.

473

474

475 **Figure legends**

476 **Figure 1. Reactivity of ZIKV patients' serum IgG and IgM antibodies against primary** 477 **cultured rat DRG neurons and Schwann cells.**

478 Immunofluorescent assay photomicrographs using ZIKV-GBS patients' serum samples
479 showing strong IgG (**A**) or IgM (**B**) antibody reactivity against DRG neurons, strong IgG (**C**)
480 and IgM (**D**) antibody reactivity against Schwann cells compared to the negative control
481 (CON) human sera which showed negligible/weak non-specific IgG (**E**) or IgM (**F**) antibody
482 reactivity against DRG neurons or IgG (**G**) or IgM (**H**) antibody reactivity against Schwann
483 cells. The percentage of IgG and IgM reactive antibodies of different intensities (0 =
484 negative, 1 = weak, 2 = moderate and 3 = strong) from the different human patient groups
485 (ZIKV-GBS, ZIKV-OND, ZIKV-CON and healthy controls (CON)) against DRG neurons,
486 Schwann cells (SCs) or either DRG/SCs are shown in **I**, **J** and **K** respectively and the p-
487 values of < 0.05, < 0.01 or < 0.001 are shown as *, **, and *** respectively.

488 **Figure 2. Patterns of ZIKV patients' serum IgG reactivity against myelinating cell co-** 489 **cultures.**

490 Examples of immunofluorescent photomicrographs of IgG binding patterns (green) of
491 different ZIKV-GBS and ZIKV-CON patients' sera in myelinated nerve cell cultures. (**A**) The
492 selective labelling of individual internodes by IgG antibodies from one female ZIKV-GBS
493 patient (*ZN060A*, 31-35 years old) with the AMAN subtype (a similar IgG binding pattern was
494 seen in one other male ZIKV-GBS patient (*Cali006*, 41-45 years old)). (**B**) Myelin
495 outpouchings or 'blebs' labelled by IgG autoantibodies in the serum of a female ZIKV-GBS
496 patient (patient D, *ZN005A*, 46-50 years old) with the AIDP subtype. (**C**) Myelin paranodes
497 (arrows) and Schmidt-Lanterman incisors (arrow heads) labelled by IgG autoantibody
498 reactions from the serum of a male ZIKV-GBS patient (*ZN039A*, 16-20 years old) with AIDP
499 subtype. (**D**) Axonal and labelling with enrichment at the node shown by IgG autoantibody
500 reactions from the serum of a male ZIKV-GBS patient (patient A, *Cali077*, 41-45 years old)
501 fatal case. Nodal regions corresponding to insets in (C) and (D) are shown on the far right.
502 (**E**) The labelling of the abaxonal membranes of all myelinating Schwann cells by the IgG
503 autoantibodies in the serum of a female ZIKV-CON patient (patient B, *BQ008*, 41-45 years
504 old) with previous uncomplicated ZIKV infection. Note that the staining is particularly intense
505 at the Schwann cell microvilli overlying the node of Ranvier (right). Co-cultures are
506 counterstained with NF200 (blue) and myelin basic protein (MBP) (red). Scale bars 5, 10 or
507 20 μm as indicated.

508 **Figure 3. Complement-dependent demyelinating activity of ZIKV patients' sera.**

509 The autoantibodies in the sera of ZIKV-CON patient B reacted with myelin internodes and
510 fixed complement (C3c deposition; green) over myelin internodes (MBP; red) when
511 complement was present from 20% normal human sera (NHS) (**A**) but not when only NHS
512 was added to the cells (**B**). Counterstaining for NF200 (blue) and MBP (red) are also shown.
513 (**C**) Fluoromyelin labelling (red) from live imaging of a myelinated co-culture before (*above*)
514 and 16h after (*below*) incubation with patient B's serum at a 1:50 dilution in the presence of
515 complement in 20% NHS, while (**D**) shows the results of time-lapse stills of the receding
516 myelin internode junctions shown from right to left over time (arrows). (**E/E'**) shows the
517 overlaid example images of live myelin staining at baseline (red) and after 24h incubation
518 (silver) with patient B's serum with or without 20% containing complement. (**E'**) shows
519 numerous myelin internodes are either lost completely or extensively fragmented after 24h
520 (shown by arrows), while (**E**) without NHS containing complement the distribution of the
521 myelin was essentially unchanged over 24h. (**F**) The total myelin length was reduced at 24h
522 (**F**, *** $p < 0.001$, one-way ANOVA with Bonferroni correction). (**G**) The number of myelin
523 segments increased, (**G**, * $p < 0.05$, one-way ANOVA with Bonferroni correction) in cultures
524 treated with patient B's serum with NHS containing complement compared to all control
525 conditions ($n=3$ per group). (**H**) The mean internodal length was also significantly reduced at
526 24h compared to baseline in ZIKV-CON+NHS group only (**H**, **** $p < 0.0001$, 2-way ANOVA
527 with Sidak's correction).

528 **Figure 4. Transfected cell-based assays confirm pan-neurofascin reactivity of IgG**
529 **antibodies within the serum of a patient with fatal, ZIKV-associated GBS.**

530 Immunofluorescent photomicrographs of (**A**) ZIKV-GBS patient A's serum antibodies,
531 reactive to unknown antigen enriched in axolemma and (**B**) a positive control patient's serum
532 with autoantibodies against the known nerve membrane antigen CNTN1 showed strong IgG
533 (green) reactions against myelinated co-cultures, as well as in neuronal monocultures
534 treated with (**C**) patient A's serum, (**D**) the anti-CNTN1+ serum. (**E**) Healthy control serum
535 was negative. Patient A's IgG serum autoantibodies also reacted with HEK cells expressing
536 the recombinant the NK155 (**F**) and NF186 (**G**) protein isoforms. Co-cultures are
537 counterstained with NF200 (blue) and myelin basic protein (MBP) (red). Scale bars, 20 and
538 50 μm as shown.

539

540 **Figure 5. Identification of a ZIKV patient's autoantibodies against myelin antigen:**
541 **Immunoprecipitation and peptide mass spectrometry.**

542 Immunofluorescent photomicrographs of (A) a positive control patient's serum with
543 autoantibodies against the known nerve antigen NF155 and (B) ZIKV-CON patient B's
544 serum autoantibody reactions against unknown antigens enriched in abaxonal myelin, with
545 higher magnifications of the nodal regions shown as insets (far right). Scale bars, 20 μ m.
546 Counterstaining for NF200 (blue) and MBP (red) are also shown. (C) Proteins identified in
547 immunoprecipitates from ZIKV serum and NF155+ serum-treated co-culture lysates. t-test of
548 enriched proteins presented as a volcano plot. iPSC lines from four donors were used to
549 generate myelinating co-cultures, and immunoprecipitates were purified and analysed by
550 mass spectrometry to give four biological replicates per serum sample. Significant data
551 points were determined with a permutation-based false discovery rate (FDR) calculation
552 (threshold = 0.1) and the significantly enriched membrane proteins are shown as red
553 squares. NFASC (neurofascin) protein isoforms from a human and rat database are grouped
554 together (blue circle). TGBR3, transforming growth factor receptor 3; AHNAK2, desmoyokin;
555 SLC12A2, solute carrier 12/Na-K-2Cl cotransporter A2; NEP, neprilysin; CD44, P-
556 glycoprotein 1; ITGA6, integrin alpha 6. The remaining peptides were identified as either
557 serum components (immunoglobulin or complement proteins) or intracellular proteins. (D)
558 ZIKV-CON patient B's serum autoantibodies were however shown to be unreactive with the
559 ANXA2 calcium binding membrane binding protein expressed in transfected HEK cells using
560 immunofluorescent photomicrographic analysis.

561 **Figure 6. Removal of ZIKV-CON patient B's serum IgG autoantibody target antigen(s)**
562 **in myelinated sensory neuron cultures by lipid extraction.**

563 (A) Immunofluorescent photomicrographs of ZIKV-CON patient B's serum IgG
564 autoantibodies showing strong staining with untreated (Control) abaxonal membranes of all
565 myelinating SCs, which was particularly intense at the Schwann cell microvilli overlying the
566 node of Ranvier (arrowhead) while (B) very weakly staining these same cells after solvent
567 treatment (Solvent). The control reactions for neuronal (NF200) and myelin (MBP) markers
568 remained unchanged. For this study, the serum-treated fixed cultures were incubated with a
569 mixture of chloroform, methanol and water at a ratio of 4:8:3 for 1h on ice to remove
570 glycolipids. The white boxes indicate regions of fluorescence profiling per internode (5 x 20
571 μ m). Arrows indicate weak paranodal IgG after lipid extraction. (C) The fluorescence
572 intensity profiles of the human IgG autoantibodies and myelin basic protein (MBP)
573 immunolabelling across the internodes of control and solvent-treated cultures. Data are

574 presented as mean (\pm SEM in grey) of two internodes per field of view, 12-14 fields of view
575 from two independent experiments. **(D)** The quantification of IgG:MBP fluorescence ratio.
576 Student's unpaired t-test, $p < 0.0001$, $t = 5.053$, $n = 24-28$ internode profiles per group.

577

578 **Supplementary Figure 1. Diagram illustrating the patient cohorts and the**
579 **experimental work flow with their serum samples.** The numbers of patients' serum
580 samples collected in the different categories of ZIKV-GBS (ZIKV patients who developed
581 GBS), ZIKV-OND (ZIKV patients who displayed other neurological diseases), ZIKV-CON
582 (ZIKV patients who never developed clinical neurological disease), DENV-CON (DENV
583 patients who never developed clinical neurological disease), ALS (patients with amyotrophic
584 lateral sclerosis, a progressive nervous system disease that affects nerve cells in the brain
585 and spinal cord, causing loss of muscle control), Dysferlin (patients with dysferlinopathy, a
586 muscle diseases that have a slow progression of muscle weakness and atrophy) and
587 healthy controls (n , number of patient samples). The patients' serum samples were initially
588 screened for their autoantibody reactions against different neuronal cell culture types and
589 from which the sera from Patients A to D were tested further for their reactions in further
590 assays.

591 **Supplementary Figure 2. Simplified heat map showing all screening performed in**
592 **ZIKV-GBS, ZIKV-OND, ZIKV-CON, DENV-CON, ALS, Dysferlin (DYS) and healthy**
593 **controls (CON) patients.** The reaction scores for each patients' IgG and IgM antibodies
594 from each group (ordered alphanumerically) against ZIKV (ELISA), rat dorsal-root ganglia
595 neurons (DRG) and Schwann cells (SC) are shown by their colour intensity of each square
596 (0=negative, 1=mild positive, 2=moderate positive, 3=strong positive), while their IgG and
597 IgM antibody reactions with the myelinating cell co-cultures (CC) were scored as either
598 negative (0) or positive (3). The serum samples that were not tested on a particular assay
599 (due to lack of sample or availability) appear blank (ND, not determined).

600 **Supplementary Figure 3. Glycolipid microarray results.**

601 Graphical display of the IgG **(A)** and IgM **(B)** antibody reaction intensities presented as heat
602 maps from blue (negative) to red (strong) for each patients' serum sample from each
603 clinically classified group (ZIKV-GBS, ZIKV-OND, ZIKV-CON, CON) when reacted against
604 136 different glycolipid targets shown in the 136 rows. No significant differences were
605 observed between the IgG or IgM antibody reactions against glycolipids and glycolipid
606 complexes of the ZIKV-GBS patients compared with those of the control group (CON).

607 **Supplementary Figure 4. Patterns of ZIKV serum IgM reactivity against myelinating**
608 **cell co-cultures.**

609 Immunofluorescent photomicrographs of IgM autoantibodies (**A**) from a ZIKV-GBS (AIDP)
610 patient's sera (patient D, *ZN005A*) with deposition on individual myelin internodes, (**B**) from
611 a male ZIKV-CON patient's serum (patient X, *ZN039B*, 41-45 years old) with deposition on
612 non-myelinating Schwann cell processes, (**C**) from a female ZIKV-CON patient's serum
613 (patient Y, *Z040*, 51-55 years old) showing strong reactivity against myelin outpouchings and
614 **D**) from another female ZIKV-CON patient's serum (patient Z, *Z010*, 81-85 years old)
615 showing weak reactivity against the myelin outpouchings. Counterstaining for NF200 (blue)
616 and MBP (red) are also shown. Scale bars, 10 μ m. The dashed lines illustrate the
617 transection of myelin outpouchings and internodes for profile analysis of IgM signal intensity.
618 (**E** and **F**) Fluorescent intensity profile plots of patients' IgM autoantibodies (green) and
619 myelin (red) across myelin outpouchings and internodes for the (**E**) strong and (**F**) weak
620 labelling sera. (**G**) The IgM (Alexa 488) autoantibody fluorescence intensities of the ZIKV-
621 GBS and ZIKV-CON patients sera compared to the healthy controls against myelin
622 outpouchings normalised to internode labelling. One way ANOVA (all groups):
623 $F(2,106)=0.7417$, $p=0.4788$). The healthy control serum samples which had detectable anti-
624 ZIKV antibodies are represented by solid green circles.

625 **Supplementary Figure 5. Axon-binding ZIKV-GBS serum antibodies are exclusively**
626 **IgG1 subclass, but does not induce complement-mediated injury in neuronal culture.**

627 Immunofluorescent photomicrographs of (**A**) ZIKV-GBS patient A's serum IgG
628 autoantibodies reactions against myelinated sensory neuron cell co-cultures detected with
629 IgG1, IgG2, IgG3 and IgG4 subclass-specific secondary antibodies and a subsequent
630 fluorescent-labelled tertiary antibody (green) with NF200 labelling used as control counter-
631 stain (blue). (**B**) Complement-induced injury to sensory neuron cell co-cultures. Incubation
632 with ZIKV-GBS patient A's serum at a 1:100 dilution or the anti-ganglioside antibody HA1 at
633 50 μ g/ml for 1 hr followed by the addition of 20% normal human sera (NHS) containing
634 complement overnight prior to fixation and immunolabelling. ZIKV-GBS patient A's serum
635 IgG autoantibody and HA1 binding were detected by fluorescent-labelled anti-human IgG
636 and anti-human IgM secondary antibodies, respectively. Note the presence of axonal
637 swellings (white arrows) and the reduced axon density in the HA1-treated cultures incubated
638 with 20% NHS. No evidence of axonal injury was observed in the cultures pre-treated with
639 the ZIKV-GBS patient A's serum prior to NHS. Scale bars, 20 μ m.

640 **Supplementary Figure 6. ZIKA-CON patient B's sera autoantibodies predominantly of**
641 **the IgG1 subclass.**

642 Immunofluorescent photomicrographs of the ZIKV-CON patient B's serum autoantibodies
643 against myelinating SC abaxonal-membranes and detection with either a pan-IgG subclass
644 reactive or IgG1, IgG2, IgG3 and IgG4 subclass-specific secondary antibodies and a
645 subsequent fluorescent-labelled tertiary antibody (green) showing their IgG autoantibodies
646 predominantly of the IgG1 subclass but also with weaker IgG4 subclass antibodies.
647 Counterstaining for NF200 (blue) and MBP (red) are also shown. Scale bars, 20 μ m.

648 **Supplementary Figure 7. ZIKV-CON patient B's IgG autoantibody reactions against**
649 **nerve cell lysates in a western blotting assay.**

650 Different protein concentrations (10, 20 and 40 μ g) of myelinated cell co-culture, sensory
651 neuron and SC monoculture lysates were subjected to discontinuous acrylamide gel
652 electrophoresis and then transferred onto nitrocellulose membranes. Western blotting with
653 ZIKV-CON patient B's serum was followed by sequential steps using peroxidase labelled
654 anti-IgG secondary antibodies and ECL substrate and photographic detection. Two protein
655 bands in the myelinated cell co-cultured lysate of relative molecular weights (Mr) of
656 approximately 62 and 50 kDa were strongly detected by the serum IgG antibodies, but not in
657 the neuronal or Swann cell lysates. The Mr standards of 52, 39, 31 and 24 kDa are shown in
658 lane 1.

659 **Supplementary Figure 8. Human anti-contactin-1 (CNTN-1) serum IgG binding is not**
660 **affected by lipid extraction.**

661 Immunofluorescent photomicrographs of the reactions of a diluted human serum which
662 contained IgG antibodies against the GPI-linked protein CNTN1 added to myelinated
663 sensory neuron cell co-cultures, followed either by (A) immediate (Control) immunolabelling
664 for bound human IgG and neuronal (neurofilament, NF200) proteins or by solvent treatment
665 (Solvent) prior to immunolabelling for bound human IgG and neuronal (neurofilament,
666 NF200) proteins. Scale bars, 20 μ m. (B) Quantification of the immunofluorescence labelling
667 intensities for NF200 and human IgG antibodies per field of view were expressed as a
668 percentage of the total area and showed that there was no significant loss of NF200 or
669 human IgG-labelled immunofluorescence after before (Control) and after solvent treatment
670 (Solvent). Identical acquisition and threshold settings were used for each field of view for
671 each condition. The Student's unpaired t-tests were used for these comparisons.

672 **Supplementary Figure 9. Effect of neuraminidase treatment of myelinating co-cultures**
673 **on the reaction of ZIKV-CON patient B's serum IgG autoantibodies**

674 Immunofluorescent photomicrographs of live myelinating co-cultures treated with either (A)
675 PBS containing divalent cations for 14 h (D-PBS) or (B) 1U/ml of neuraminidase for 14h
676 (Neuraminidase) prior to addition of ZIKV-CON patient B's serum IgG autoantibodies and
677 the fluorescent labelled secondary antibodies or control labelling of NF200 and MBP. Scale
678 bars, 10 μ m. (C) The fluorescence intensity profiles (AU) of human IgG and MBP
679 immunolabelling across internodes of control and solvent-treated cultures. The data are
680 presented as the mean values (\pm SEM in grey) of two internodes per field of view, 6 fields of
681 view from two independent experiments. (D) The quantification of IgG:MBP fluorescence
682 ratios with the Student's unpaired t-test, $p=0.3605$, $t=0.9340$, $n=12$ internode profiles per
683 group.

684 **Supplementary Figure 10. Sialic acid cleavage by neuraminidase treatment reduces**
685 **binding of anti-disialosyl ganglioside but not anti-CNTN1 antibodies.**

686 Immunofluorescent photomicrographs of the reactions of (A) anti-GD2, (C) anti-GD3 anti-
687 disialosyl ganglioside and (E) anti-CNTN1 GPI-linked protein antibodies (green) against live
688 myelinating co-cultures after treatment with either 1U/ml of neuraminidase or D-PBS vehicle
689 for 14 h. Counterstaining for NF200 (blue) and MBP (red) are also shown. Scale bars, 20
690 μ m. The coverage of (B) anti-GD2, (D) anti-GD3 and (F) anti-CNTN1 IgG in the PBS and
691 neuraminidase treated cultures expressed as a percentage of axon NF200 area.

692 **References**

- 693 1 Cao-Lormeau, VM, Blake, A, Mons, S *et al.*, Guillain-Barre Syndrome outbreak associated
694 with Zika virus infection in French Polynesia: a case-control study. *Lancet*
695 2016;387(10027):1531-1539.
- 696 2 Dos Santos, T, Rodriguez, A, Almiron, M *et al.*, Zika Virus and the Guillain-Barre
697 Syndrome - Case Series from Seven Countries. *N Engl J Med* 2016;375(16):1598-
698 1601.
- 699 3 Parra, B, Lizarazo, J, Jimenez-Arango, JA *et al.*, Guillain-Barre Syndrome Associated with
700 Zika Virus Infection in Colombia. *N Engl J Med* 2016;375(16):1513-1523.
- 701 4 Keegan, LT, Lessler, J and Johansson, MA, Quantifying Zika: Advancing the Epidemiology
702 of Zika With Quantitative Models. *J Infect Dis* 2017;216(suppl_10):S884-S890.
- 703 5 Moore, SM, Oidtman, RJ, Soda, KJ *et al.*, Leveraging multiple data types to estimate the
704 size of the Zika epidemic in the Americas. *PLoS Negl Trop Dis* 2020;14(9):e0008640.
- 705 6 Uncini, A, Shahrizaila, N and Kuwabara, S, Zika virus infection and Guillain-Barre
706 syndrome: a review focused on clinical and electrophysiological subtypes. *J Neurol*
707 *Neurosurg Psychiatry* 2017;88(3):266-271.
- 708 7 Uncini, A, Gonzalez-Bravo, DC, Acosta-Ampudia, YY *et al.*, Clinical and nerve conduction
709 features in Guillain-Barre syndrome associated with Zika virus infection in Cucuta,
710 Colombia. *Eur J Neurol* 2018;25(4):644-650.
- 711 8 Munoz, LS, Parra, B, Pardo, CA *et al.*, Neurological Implications of Zika Virus Infection in
712 Adults. *J Infect Dis* 2017;216(suppl_10):S897-S905.
- 713 9 Koma, T, Veljkovic, V, Anderson, DE *et al.*, Zika virus infection elicits auto-antibodies to
714 C1q. *Sci Rep* 2018;8(1):1882.
- 715 10 Lynch, RM, Mantus, G, Encinales, L *et al.*, Augmented Zika and Dengue Neutralizing
716 Antibodies Are Associated With Guillain-Barre Syndrome. *J Infect Dis* 2019;219(1):26-
717 30.

- 718 11 Rivera-Correa, J, de Siqueira, IC, Mota, S *et al.*, Anti-ganglioside antibodies in patients
719 with Zika virus infection-associated Guillain-Barre Syndrome in Brazil. *PLoS Negl Trop*
720 *Dis* 2019;13(9):e0007695.
- 721 12 Medina, MT, England, JD, Lorenzana, I *et al.*, Zika virus associated with sensory
722 polyneuropathy. *J Neurol Sci* 2016;369:271-272.
- 723 13 Oh, Y, Zhang, F, Wang, Y *et al.*, Zika virus directly infects peripheral neurons and
724 induces cell death. *Nat Neurosci* 2017;20(9):1209-1212.
- 725 14 Volpi, VG, Pagani, I, Ghezzi, S *et al.*, Zika Virus Replication in Dorsal Root Ganglia
726 Explants from Interferon Receptor1 Knockout Mice Causes Myelin Degeneration. *Sci*
727 *Rep* 2018;8(1):10166.
- 728 15 Anaya, JM, Rodriguez, Y, Monsalve, DM *et al.*, A comprehensive analysis and
729 immunobiology of autoimmune neurological syndromes during the Zika virus outbreak
730 in Cucuta, Colombia. *J Autoimmun* 2017;77:123-138.
- 731 16 Gallo, V, Egger, M, McCormack, V *et al.*, STrengthening the Reporting of OBServational
732 studies in Epidemiology - Molecular Epidemiology (STROBE-ME): an extension of the
733 STROBE statement. *Eur J Clin Invest* 2012;42(1):1-16.
- 734 17 Siles, AM, Martinez-Hernandez, E, Araque, J *et al.*, Antibodies against cell adhesion
735 molecules and neural structures in paraneoplastic neuropathies. *Ann Clin Transl*
736 *Neurol* 2018;5(5):559-569.
- 737 18 Clark, AJ, Kaller, MS, Galino, J *et al.*, Co-cultures with stem cell-derived human sensory
738 neurons reveal regulators of peripheral myelination. *Brain* 2017;140(4):898-913.
- 739 19 Davies, AJ, Fehmi, J, Senel, M *et al.*, Immunoabsorption and Plasma Exchange in
740 Seropositive and Seronegative Immune-Mediated Neuropathies. *J Clin Med*
741 2020;9(7):2025.
- 742 20 Halstead, SK, Kalna, G, Islam, MB *et al.*, Microarray screening of Guillain-Barre
743 syndrome sera for antibodies to glycolipid complexes. *Neurol Neuroimmunol*
744 *Neuroinflamm* 2016;3(6):e284.

- 745 21 Willison, HJ, Veitch, J, Swan, AV *et al.*, Inter-laboratory validation of an ELISA for the
746 determination of serum anti-ganglioside antibodies. *Eur J Neurol* 1999;6(1):71-7.
- 747 22 Dejnirattisai, W, Supasa, P, Wongwiwat, W *et al.*, Dengue virus sero-cross-reactivity
748 drives antibody-dependent enhancement of infection with zika virus. *Nat Immunol*
749 2016;17(9):1102-8.
- 750 23 Fehmi, J, Davies, AJ, Antonelou, M *et al.*, Contactin-1 Antibodies Link Autoimmune
751 Neuropathies to Nephrotic Syndrome. *SSRN* 2020:<https://ssrn.com/abstract=3739819>.
- 752 24 Svennerholm, L and Fredman, P, A procedure for the quantitative isolation of brain
753 gangliosides. *Biochim Biophys Acta* 1980;617(1):97-109.
- 754 25 Leonhard, SE, Halstead, S, Lant, SB *et al.*, Guillain-Barre syndrome during the Zika virus
755 outbreak in Northeast Brazil: An observational cohort study. *J Neurol Sci*
756 2021;420:117272.
- 757 26 Lucchese, G and Kanduc, D, Zika virus and autoimmunity: From microcephaly to
758 Guillain-Barre syndrome, and beyond. *Autoimmun Rev* 2016;15(8):801-8.
- 759 27 Sanchez, OA, Portillo, KM, Reyes-Garcia, SZ *et al.*, Characterization of adult patients
760 with Guillain-Barre syndrome during the arboviral infection outbreaks in Honduras. *J*
761 *Neurol Sci* 2021;427:117551.
- 762 28 Fehmi, J, Davies, AJ, Walters, RJ *et al.*, IgG1 pan-neurofascin antibodies identify a
763 severe yet treatable neuropathy with a high mortality. *medRxiv*
764 2021:2021.01.29.21250485.
- 765 29 Sander, S, Ouvrier, RA, McLeod, JG *et al.*, Clinical syndromes associated with tomacula
766 or myelin swellings in sural nerve biopsies. *J Neurol Neurosurg Psychiatry*
767 2000;68(4):483-8.
- 768 30 Querol, L, Siles, AM, Alba-Rovira, R *et al.*, Antibodies against peripheral nerve antigens
769 in chronic inflammatory demyelinating polyradiculoneuropathy. *Sci Rep*
770 2017;7(1):14411.

- 771 31 Freeth, J and Soden, J, New Advances in Cell Microarray Technology to Expand
772 Applications in Target Deconvolution and Off-Target Screening. *SLAS Discov*
773 2020;25(2):223-230.
- 774 32 Wang, EY, Dai, Y, Rosen, CE *et al.*, REAP: A platform to identify autoantibodies that
775 target the human exoproteome. *bioRxiv* 2021:2021.02.11.430703.
- 776 33 Jeong, JS, Jiang, L, Albino, E *et al.*, Rapid identification of monospecific monoclonal
777 antibodies using a human proteome microarray. *Mol Cell Proteomics* 2012;11(6):O111
778 016253.
- 779 34 Moritz, CP, Tholance, Y, Stoevesandt, O *et al.*, CIDP Antibodies Target Junction Proteins
780 and Identify Patient Subgroups: An Autoantigenomic Approach. *Neurol Neuroimmunol*
781 *Neuroinflamm* 2021;8(2).
- 782 35 Lleixà, C, Martín-Aguilar, L, Pascual-Goñi, E *et al.*, Autoantibody screening in Guillain-
783 Barré Syndrome. *Journal of Neuroinflammation* 2021;(in press).
- 784

Figure 1.




Figure 2.




Figure 3.




Figure 4.




Figure 5








Figure 6.





Supplementary Figure 1.










Supplementary Figure 2.




Supplementary Figure 3.




Supplementary Figure 4.




Supplementary Figure 5.




Supplementary Figure 6.




Supplementary Figure 7.



Supplementary Figure 8.



Supplementary Figure 9.



Supplementary Figure 10.

